Cord Blood America, Inc. (OTC Bulletin Board:CBAI.ob), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, has purchased controlling interest, 50.1 percent, of Biocordcell Argentina S.A. (BioCells, Inc.).
BioCells is headquartered in Argentina, with affiliates under development in Peru, Colombia, Bolivia, Panama and Puerto Rico, and recent expansion into Uruguay and Paraguay. Purchase price for the profitable stem cell storage company, the second largest in Argentina, depends on achieving earn out targets for net profit over the next two years.
BioCells is profitable, with annual revenues in 2009 of $1.2 million (U.S.), and 12 locations throughout that nation of 40 million people that saves umbilical cord blood stem cells at a rate even higher than in the U.S. “This is an historic day for Cord Blood America, our loyal investors and stakeholders. We will not rest until we meet our goal of becoming the world’s premier stem cell storage company,” Mr. Schissler said.
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.
BSD Medical Corporation (NASDAQ: BSDM) reports that a patent has been issued to the Company for a new class of heat therapy applicators (antennas). The United States (US) patent office issued the new patent, �Transparent electromagnetic applicator and hyperthermia treatment method,� to BSD for a unique design for antennas that provides significant benefits for heat therapy applications. These novel antennas have a transparent surface, which provides the significant advantage of allowing the physician to see the skin surface through the contacting antenna during a treatment. The unique design also utilizes a significantly smaller antenna that can be combined in groups to utilize BSD�s synchronous phased array technology, which was developed by the Company to improve the delivery of heat therapy by directly targeting heating to the tumor. There are five different antenna types and sizes that are part of this new class of antenna, which allows BSD to combine up to 24 antennas into a single applicator and utilize sophisticated heating pattern steering to shape the energy field to the individual tumor. BSD has been designing heat therapy systems for 32 years and has obtained several pioneering patents for the devices, techniques and methodology used in heat therapy.
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD�s product lines include both hyperthermia and ablation treatment systems. BSD�s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD�s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company�s products have received regulatory approvals and clearances in the United States, Europe and China.
No comments:
Post a Comment